Taurolidine positive in vitro (mouse lymphoma and Ames) regardless of metabolic activation; negative in vivo
“Although taurolidine is positive for genotoxicity in vitro regardless of metabolic activation (mouse lymphoma and Ames tests), it is negative in vivo.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Carcinogenicity
Not conducted (not for systemic administration; negligible clinical exposure)
“Carcinogenicity studies were not needed for Defencath because the product is not intended for systemic administration and clinical exposure to its components is negligible when used as directed.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Reproductive & developmental
Not conducted; waived because the product is not for systemic administration
“Reproductive and developmental toxicology studies were waived for Defencath because the product is not intended for systemic administration and clinical exposure to its components is negligible when used as directed.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Safety pharmacology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative